Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History

Walleye Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.8K	Sell	200 -600	-75%	-$104K	﹤0.01%	3987
2025 Q4	$146K	Hold	800	–	–	﹤0.01%	3700
2025 Q3	$97.2K	Sell	800 -9,200	-92%	-$1.04M	﹤0.01%	3727
2025 Q2	$1.04M	Buy	10,000 +4,800	+92%	+$508K	﹤0.01%	2012
2025 Q1	$606K	Buy	5,200 +1,000	+24%	+$114K	﹤0.01%	2392
2024 Q4	$355K	Sell	4,200 -1,200	-22%	-$110K	﹤0.01%	3279
2024 Q3	$485K	Buy	5,400 +900	+20%	+$78.6K	﹤0.01%	3322
2024 Q2	$362K	Sell	4,500 -800	-15%	-$59.2K	﹤0.01%	3799
2024 Q1	$423K	Buy	5,300 +2,700	+104%	+$227K	﹤0.01%	3339
2023 Q4	$207K	Sell	2,600 -2,100	-45%	-$140K	﹤0.01%	3652
2023 Q3	$328K	Buy	4,700 +200	+4%	+$15K	﹤0.01%	3164
2023 Q2	$323K	Buy	+4,500	New	+$332K	﹤0.01%	2732
2023 Q1	–	Sell	-8,600	Closed	-$663K	–	3933
2022 Q4	$663K	Buy	8,600 +6,600	+330%	+$394K	0.01%	1259
2022 Q3	$89K	Buy	+2,000	New	+$99.9K	﹤0.01%	2463

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's AXSM Position: Q1 2026 in Review

Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 42% in Q1 2026, selling an estimated $4.31M and leaving 35,119 shares worth $5.94M. The position accounts for 0.02% of the portfolio, ranked #701.

Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 13 quarters since. The position peaked at $17.6M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Walleye Capital held 35,119 shares of Axsome Therapeutics worth $5.94M as of Q1 2026.
Walleye Capital sold 24,981 Axsome Therapeutics shares in Q1 2026, an estimated $4.31M.
Axsome Therapeutics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #701 holding.
Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 13 quarters since.
Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.